Last reviewed · How we verify

NCT04810702: WILLANGIO

Impact of Von Willebrand Factor and Its Multimers on Angiogenesis

Status unknown Last updated 22 March 2024
What this trial tests

trial testing no intervention in Von Willebrand Diseases in 90 participants. Status unknown.

Timeline
7 February 2024
Primary endpoint
7 August 2024
7 August 2024

Quick facts

Lead sponsorNantes University Hospital
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment90
Start date7 February 2024
Primary completion7 August 2024
Estimated completion7 August 2024
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Nantes University Hospital

Who can join

18 and older, any sex, with Von Willebrand Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study aims to study the expression of numerous proteins involved in angiogenesis in 70 patients with von Willebrand disease in order to try to identify markers of interest. Secondly, the investigators plan to investigate whether there is a relationship between the proteins tested, the distribution of multimers and the clinical phenotype of the patients, in particular by looking for the presence of bleeding linked to the presence of angiodysplasias.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of no intervention

Trials testing the same drug.

Other recruiting trials for Von Willebrand Diseases

Currently open trials in the same condition.

Other Nantes University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04810702.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing